Login / Signup

Humoral response and safety of the third booster dose of BNT162b2 mRNA COVID-19 vaccine in patients with multiple sclerosis treated with ocrelizumab or fingolimod.

Rocco CapuanoManuela AltieriMiriana ConteAlvino BiseccoAlessandro d'AmbrosioGiovanna DonnarummaElena GrimaldiNicola CoppolaNicola MediciMassimiliano GaldieroGioacchino TedeschiAntonio Gallo
Published in: Journal of neurology (2022)
The third booster dose of BNT162b2 mRNA vaccine to OCR- and FNG-treated pwMS revives the humoral response, independently of any clinical variable, and manifests a good safety and tolerability profile.
Keyphrases
  • immune response
  • coronavirus disease
  • multiple sclerosis
  • sars cov
  • clinical trial
  • newly diagnosed